Clinical trials
Multiple Sclerosis (MS) Primary Progressive clinical trials
Below are recruiting multiple sclerosis (ms) primary progressive clinical trials, each written for real people, not researchers. We’re tracking 58 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06845722Recruiting
Balance and cognitive training for multiple sclerosis
This trial tests whether combining balance exercises with brain-training activities can help improve walking and thinking in people with multiple sclerosis. It is for people aged 40–55 who have mild cognitive problems and balance issues.
LahoreAges 40–55 - NCT06901687RecruitingPhase 2
Home brain stimulation for depression in MS
This study tests whether a special, gentle brain stimulation device you can use at home (called tDCS) can help improve depression symptoms in people with multiple sclerosis. You will be supervised over video during the sessions to make sure everything goes smoothly.
New York, New YorkAges 18–65 - NCT07011914Recruiting
MS care study for young adults
This study looks at how to improve care for young adults with relapsing-remitting MS. It focuses on people who are Black, Hispanic, or have limited income.
Birmingham, AlabamaAges 18 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07222618Recruiting
Selfie videos to measure function in MS
This trial asks people with MS to record short 'selfie' videos of themselves doing everyday tasks, like walking or getting dressed. The goal is to find a better, more personal way to measure how MS affects daily function.
San Francisco, CaliforniaAges 18 years+ - NCT05359653RecruitingPhase 1/Phase 2
Clemastine to study MRI changes in relapsing MS
This early-phase study tests whether clemastine (a drug being studied for “myelin repair”) changes how MS looks on special MRI scans. It may help researchers understand if the treatment supports restoring nerve covering in people with relapsing-remitting MS.
San Francisco, CaliforniaAges 18–55 - NCT07303790RecruitingEarly Phase 1
Study of GC012F for people with multiple sclerosis
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hubei, HubeiAges 18 years+ - NCT07355387Recruiting
Home-based balance training for multiple sclerosis
This study tests a 12-week home-based balance training program for people with multiple sclerosis. Sessions are done online with a helper present, and the goal is to improve walking and reduce fall risk.
Chicago, IllinoisAges 40–90 - NCT07392879Recruiting
Virtual nature walks for depression in MS
This study tests whether virtual reality nature walks can help improve depression in people with progressive multiple sclerosis. You will use a VR headset at home to watch calming nature scenes, and researchers will see how it affects your mood.
Ann Arbor, MichiganAges 18 years+ - NCT01703429Recruiting
Alternative care program for people with multiple sclerosis
This study looks at how a complementary or alternative care approach affects people living with multiple sclerosis. It may help to understand whether this type of program improves symptoms or quality of life over time.
Kenmore, WashingtonAges 18–100 - NCT07426991Recruiting
Multiple sclerosis, thinking, sleep, and tiredness study
This study looks at how multiple sclerosis (MS) affects your thinking, sleep, and tiredness. It compares people with MS who have at least mild fatigue to people without MS who also have sleep problems, to understand these issues better.
DüsseldorfAges 18–79 - NCT07477639RecruitingPhase 1/Phase 2
Testing TRX319 for worsening multiple sclerosis
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
Kansas City, KansasAges 18–65 - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT05162638Enrolling by invitation
Immune study in MS and healthy adults using a special tube
This study compares immune (defense system) “profiles” between people with multiple sclerosis (MS) and healthy volunteers. It involves a thoracic duct cannulation procedure and several MRIs to see how immune cells behave and whether a specific immune pattern is different in MS.
Philadelphia, PennsylvaniaAges 18–40 - NCT06846281RecruitingPhase 3
Switching to remibrutinib from ocrelizumab for relapsing MS
This study tests a new oral medication called remibrutinib for people with relapsing MS who are currently on ocrelizumab. The goal is to see if switching to remibrutinib is safe and effective for controlling MS long-term.
Scottsdale, ArizonaAges 40–70 - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT02433028Recruiting
Long-term study for MS and related nervous system conditions
This is a long-term hospital study that follows people diagnosed with MS (and a few related conditions) to understand how disease changes over time. You may be asked to have regular check-ups, brain scans, and provide blood samples so researchers can track disease and treatment effects.
Aarau, Canton of AargauAges Any age
Hear when a new Multiple Sclerosis (MS) Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis (ms) primary progressive?
- Yes. Clin2 currently lists 58 recruiting multiple sclerosis (ms) primary progressive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis (ms) primary progressive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis (ms) primary progressive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Primary Progressive Aphasia
- Multiple Sclerosis (MS) - Relapsing-remitting
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.